Get the Stockscreener App
6.42
1.08%
-0.07
Nuvation Bio Inc stock is traded at $6.42, with a volume of 6.14M.
It is down -1.08% in the last 24 hours and down -0.62% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
See More
Previous Close:
$6.49
Open:
$6.5
24h Volume:
6.14M
Relative Volume:
0.99
Market Cap:
$2.24B
Revenue:
$143.05M
Net Income/Loss:
$-145.99M
P/E Ratio:
-14.99
EPS:
-0.4282
Net Cash Flow:
$-134.06M
1W Performance:
+10.69%
1M Performance:
-0.62%
6M Performance:
+14.85%
1Y Performance:
+155.78%
1-Day Range:
$6.30
$6.61
1-Week Range:
$5.87
$6.625
52-Week Range:
$2.18
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
332-208-6102
Address
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
6.42 | 2.24B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-19-25 | Initiated | B. Riley Securities | Buy |
| Sep-30-25 | Initiated | Jefferies | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Nuvation Bio Inc (NUVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvation Bio Inc (NUVB) Institutional Confidence - TradingKey
Nuvation Bio Inc (NUVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NUVB|Nuvation Bio Inc|Price:6.420|Chg%:-0.055 - TradingKey
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug - Stocktwits
Nuvation Bio to report Q2 2026 results on August 6 - scanx.trade
Nuvation Bio To Report Second Quarter 2026 Financial Results - TradingView
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 - The Winchester Star
Nuvation Bio's Safusidenib Clinical Program, Ibtrozi Opportunity Create Favorable Setup, RBC Says - Moomoo
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential By Investing.com - Investing.com India
RBC Capital reiterates Nuvation Bio stock rating on pipeline potential - Investing.com
Truist Financial Maintains Nuvation Bio(NUVB.US) With Buy Rating - Moomoo
Frontier tech research, news & data - MLQ.ai
JonesTrading Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Developing Better Drugs, Not Just More Drugs: Q&A with David Hung - Pharmaceutical Executive
symbol__ Stock Quote Price and Forecast - CNN
Nuvation Bio stock jumps on safusidenib trial expansion plans - Investing.com India
Nuvation Bio stock jumps on safusidenib trial expansion plans By Investing.com - Investing.com Nigeria
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $19 - Moomoo
BUZZ-U.S. STOCKS ON THE MOVE-Yum Brands, AMD, Nuvation Bio - Bitget
NUVB Stock Slides On Financing As Bullish Analysts Double Down - StocksToTrade
Nuvation Bio to advance glioma drug to Phase III trial after positive three-year data - Yahoo
Nuvation Bio reports 51.9% response rate for safusidenib in Phase 2 glioma study - grafa.com
Why Is Nuvation Bio Stock Gaining Monday? - Benzinga
Nuvation Bio posts corporate deck highlighting IBTROZI ROS1+ NSCLC launch, safusidenib IDH1 glioma program - Bitget
Nuvation Bio (NUVB) Corporate presentation Summary - Quartr
Nuvation Bio expands safusidenib program with two new studies - Investing.com
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma - Investing News Network
NUVB: IBTROZI's global success and a robust pipeline drive growth in high-value oncology markets - TradingView
Nuvation Bio expands safusidenib program with two new studies By Investing.com - Investing.com Canada
Form 4 Nuvation Bio Inc For: 17 July By Investing.com - Investing.com South Africa
Nuvation Bio (NUVB) CFO exercises 40,000 share options and boosts holdings - Stock Titan
Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
How Nuvation Bio Manages its Ongoing Clinical Trials - Pharmaceutical Executive
Goodwin Advises On Nuvation Bio’s $287.5 Million Registered Convertible Senior Notes Offering With Capped Call - Mondaq
The Status of Nuvation Bio’s Pipeline - Pharmaceutical Executive
Nuvation Bio’s Global Strategy - Pharmaceutical Executive
RBC Capital Cuts PT on Nuvation Bio (NUVB) in Q2 Preview - Yahoo Finance
Is Nuvation Bio (NUVB) Fairly Valued Following UK Taletrectinib Filing Progress? - Sahm
The Origins of Nuvation Bio’s Deal with Daichii Sankyo for the Rights to Safusidenib in Japan - Pharmaceutical Executive
Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Nuvation Bio (NUVB) - The Globe and Mail
Nuvation Bio’s Approach to Building a Compelling Narrative - Pharmaceutical Executive
Can Nuvation Bio Inc (NUVB) Stock Soar 150% From Current Level? - Yahoo Finance
Does Nuvation Bio (NUVB) Have the Global Scale to Maximize Taletrectinib’s Regulatory Momentum? - Sahm
Nuvation Bio to offer $200M convertible senior notes - MSN
Nuvation Bio Inc. Class A (NUVB) Stock Price | Live Quotes & Charts | NYSE - timothysykes.com
Nuvation Bio ups convertible notes offering to $287.5M after greenshoe exercise - MSN
NUVB Maintained by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Cuts Target Price to $19 - Moomoo
NUVB Maintained by Truist Securities -- Price Target Raised to $13.00 - GuruFocus
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.46%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):